Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Overexpressed Protein Converts Noninvasive Breast Cancer into Invasive Disease

10.09.2009
Active, but non-invasive breast cancer is set free to roam as invasive breast cancer when an overexpressed protein converts it to a different cell type, scientists at The University of Texas M. D. Anderson Cancer Center report in the Sept. 9 issue of the journal Cancer Cell.

“We have discovered a key molecular mechanism for the deadly transition of non-invasive breast cancer into invasive disease,” said senior author Dihua Yu, M.D., Ph.D., professor in M. D. Anderson’s Department of Molecular and Cellular Oncology.

Overexpression of the protein 14-3-3æ (zeta) launches a molecular cascade that removes bonds that tie the premalignant cells together and hold them in place, converting them from stationary epithelial cells to highly mobile mesenchymal-like cells, Yu and colleagues report. This epithelial-to-mesenchymal transition (EMT) is recognized as a crucial step in metastasis, the spread of cancer to distant organs that causes 90 percent of all cancer deaths.

The researchers show that 14-3-3æ teams with the oncoprotein ErbB2, also known as HER2, in a two-hit process to convert normal mammary cells to invasive cancer cells.

In addition to identifying this key step in EMT, Yu notes the findings also provide:

• A biomarker in 14-3-3æ to identify high-risk patients for more aggressive treatment before their noninvasive breast cancer converts to invasive disease.

• New therapeutic targets among the components of the molecular pathway launched by 14-3-3æ. Some drugs already aim at these targets, Yu said.

• A solution to a puzzling mystery about how a subset of non-invasive breast cancer with excessive presence of a ErbB2/HER2 develops into invasive breast cancer.

Yu and colleagues previously showed that 14-3-3æ is overexpressed in many other cancer types, like lung, liver, uterine, stomach cancers. “Our findings might have broader implications relating to the mechanism of invasion and metastasis in other types of cancer,” Yu said.

Unzipping cancer cells
The team set out to address a longstanding puzzle, Yu said. ErbB2, an oncoprotein that promotes metastasis, is overexpressed in 50 to 60 percent of the noninvasive breast cancer known as ductal carcinoma in situ (DCIS). However, that same protein is overexpressed in only about 25 percent of invasive breast cancers, which seemed counterintuitive.

In a series of lab experiments, Yu and colleagues showed that overexpression of ErbB2 accompanied by overexpression of 14-3-3æ can change DCIS into invasive breast cancer. This only occurs in about half of ErbB2-overexpressing DCIS, the team found, explaining the numerical puzzle.

Overexpression of ErbB2 converts normal breast duct cells into abnormal cells that reproduce quickly, are capable of moving, and resist programmed cell death that usually kills aberrant cells. What prevents these DCIS cells from becoming invasive, Yu said, is that they are locked together in zipper-like fashion by the cell surface protein E-cadherin, a trait known as cell-cell adhesion.

“Overexpression of 14-3-3æ is the catalyst for a molecular pathway that strips E-cadherin from the cells, setting the cells loose from each other,” Yu said. These cells also change in appearance from blunt normal breast duct cells to a narrow spindle shape characteristic of a mesenchymal-like cell.

Double overexpression reduces survival time
Epithelial cells line an organ or its cavities and are generally immobile. Mesenchymal cells are mobile and can differentiate into many different cell types, for example, to repair injury. Epithelial-mesenchymal transition is known to repress E-cadherin, decrease cell-cell adhesion and increase a cell’s capacity to move. An estimated 80 percent of all solid tumors are carcinomas, cancers of the epithelial tissue.

Mice injected with a breast cancer cell line with both proteins overexpressed had three times the metastasis as mice with a control cancer cell line.

The researchers examined 107 invasive breast cancer cases and found that 23 of the cancers overexpressed both proteins. Those patients also had significantly shorter survival times due to metastasis-related deaths than those whose tumors expressed one or neither of the proteins.

Overexpressed 14-3-3æ, the team showed, interacts with and stabilizes the receptor protein TâR1, which activates smad2/3 and moves them into the cell nucleus, where they in turn increase expression of ZFHX1B, which then represses expression of the adhesion protein E-cadherin.

Yu said that it will be very challenging to target 14-3-3æ by drugs because it also regulates other important proteins in normal cellular processes. The downstream components such as TâR1 can be targeted with drugs that are under clinical trials.

Research was funded by grants from the National Cancer Institute, the U.S. Department of Defense Center of Excellence Grant and a synergistic Award, a Susan G. Komen Breast Cancer Foundation Promise Grant and the Royal Golden Jubilee Program of the Thailand Research Fund.

Co-authors with Yu are first author Jing Lu, Ph.D., Hua Guo, M.D., Warapen Treekitkammongkol, Ph.D., Ping Li, Jian Zhang, Ph.D., Bin Shi, Ph.D., Xiaoyan Zhou, M.D., Ph.D., Tongzhen Chen, M.D., and Mien-Chie Hung, Ph.D., all of the Department of Molecular and Cellular Oncology; Hung also is associated with China Medical University and Hospital in Taiwan; Paul Chiao, Ph.D., of M. D. Anderson’s Department of Surgical Oncology; Ayesegui Sahin, M.D., of M. D. Anderson’s Department of Pathology; Chen Ling of the Molecular Oncology Group, McGill University Health Center in Montreal; Xinhua Feng, Ph.D., of the Department of Molecular and Cellular Biology, Baylor College of Medicine; and Victoria Seewaldt, M.D., of the Duke University Department of Medicine.

About M. D. Anderson
The University of Texas M. D. Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. M. D. Anderson is one of only 40 comprehensive cancer centers designated by the National Cancer Institute. For six of the past eight years, including 2009, M. D. Anderson has ranked No. 1 in cancer care in “America's Best Hospitals,” a survey published annually in U.S. News & World Report.

Scott Merville | Newswise Science News
Further information:
http://www.mdanderson.org

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Physics boosts artificial intelligence methods

19.10.2017 | Physics and Astronomy

NASA team finds noxious ice cloud on saturn's moon titan

19.10.2017 | Physics and Astronomy

New procedure enables cultivation of human brain sections in the petri dish

19.10.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>